Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0G8LN
|
|||
| Former ID |
DCL001202
|
|||
| Drug Name |
ISIS-SGLT2
|
|||
| Drug Type |
Antisense drug
|
|||
| Indication | Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Phase 1 | [1] | |
| Company |
ISIS Pharm
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | SLC5A2 messenger RNA (SLC5A2 mRNA) | Target Info | . | [1] |
| Reactome | Hexose transport | |||
| Na+-dependent glucose transporters | ||||
| Inositol transporters | ||||
| WikiPathways | NRF2 pathway | |||
| Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.